Researches

South Egypt Cancer Institute

Assiut University

# Title Department Research Member Research Year
41 Pediatric cancer mortality: Analyzing early deaths and fatalities in a resource-limited tertiary care context Department of Pediatric Oncology Ahmed Abdelwahab Faraag Mohammed 2024
42 Analgesia and safety of perioperative bilateral erector spinae infusion versus thoracic epidural infusion in upper abdominal oncological surgeries. Department of Anesthesia, Intensive care and Pain management Mohamed Hussein Mahmoud Ahmed 2024
43 Diagnostic efficacy of Ovarian-Adnexal Reporting and Data System (ORADS) in Evaluation of Ovarian Lesions Department of Radiology Dr. Doaa Mohamed Fouad Mahmoud 2024
44 Analgesic effect of nulbuphine -bupivacaine combination in ultrasound guided Transverses abdominis plane block in patients undergoing major abdominal cancer surgeries. Department of Anesthesia, Intensive care and Pain management Dr. Shereen Mamdoh Mohamed kamal 2024
45 Field and Nodal Irradiation in Early stage Hodgkin’s lymphoma: A single institution study Department of Radiotherapy and Nuclear medicine Dr. Asmaa elsayed abdelsalam /hasaballah 2024
46 Beta Endorphins, Interleukin 1 and Interleukin 38 in Covid Patients Associated with Neuropsychological Manifestations Department of Clinical Pathology Prof. Eman Massad Zaki El-Hefny 2024
47 Prognostic Value of Vitamin D Receptor in Patients with Metastatic Colorectal Cancer Received Irinotecan-Based Systemic Treatment as a Second Line Department of Medical Oncology Prof. Ashraf Zeidan Abdalla Ahmed 2024
48 High Dose Methotrexate Induced Toxicity in Children with Hematological Malignancy: Incidence and Relation to MTX Level Department of Pediatric Oncology Prof. Heba Abdel-Razik Sayed Hussein 2024
49 Prognostic significance of CD3+ and CD8+ T-cells immunoscore in renal cell carcinoma: A comparison between two simple models for assessment Department of Pathology Amira Emad Mohamed Elwy 2024
50 Prognostic Value of Vitamin D Receptor in Patients with Metastatic Colorectal Cancer Received Irinotecan-Based Systemic Treatment as a Second Line Department of Medical Oncology Dr. Salah Mabrouk Khallaf Abd Rabou 2024